Terumo’s PLAJEX Provides a Solution for a New Osteoporosis Treatment Developed and Manufactured on C

erumo Corporation (TSE: 4543) today announced that a new osteoporosis medication, TeriboneTM 28.2㎍ subcutaneous autoinjector, has been launched in the Japanese market for patients with a high risk of fractures. Terumo has signed a development and manufacturing contract with Asahi Kasei Pharma Corporation. The product will be manufactured at Terumo Yamaguchi D&D Corporation and marketed by Asahi Kasei Pharma.

11/12/2019 - TOKYO, JAPAN

Asahi Kasei Pharma has been providing lyophilized vial formulation TeriboneTM 56.5㎍ subcutaneous injection, since 2011. This new product offers a new treatment option for patients. The product design enables patients to easily self-inject in a home setting.

TeriboneTM 28.2㎍ is pre-filled in Terumo's PLAJEXTM silicone oil-free syringe. The highly breakage-resistant polymer material and the low-reactive and stable characteristic of the syringe played a role in the design of this new product, which is safe for self-injection. The product is assembled with a 2-step autoinjector. Patients simply remove the cap and press the device onto the skin to complete the injection. The single dose use medication is also suitable for elderly patients on continual treatment.

Terumo will continue to strive for the expansion of their CDMO business to provide new solutions for pharmaceutical companies, and so contribute to better healthcare.